NewEdge Advisors LLC Purchases 51,116 Shares of CVS Health Corporation $CVS

Key Points

• NewEdge Advisors increased its CVS Health stake by 39% in the second quarter, purchasing 51,116 additional shares for a total of 182,038 shares valued at approximately $18.8 million.
• Other major institutions also raised their holdings, and institutional investors now own 80.66% of CVS Health. Analysts remain broadly positive, with 22 Buy ratings, one Hold rating and a consensus price target of $107.24.
• CVS reported quarterly EPS of $2.58 versus the $1.87 consensus and revenue of $106.1 billion, up 7.3% year over year, while maintaining 2026 EPS guidance of $7.90–$8.10. However, elevated medical expenses and pressure on Aetna margins remain key risks.

NewEdge Advisors LLC raised its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 39.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 182,038 shares of the pharmacy operator's stock after acquiring an additional 51,116 shares during the period. NewEdge Advisors LLC's holdings in CVS Health were worth $18,832,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Handelsbanken Fonder AB lifted its stake in shares of CVS Health by 83.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator's stock valued at $112,729,000 after acquiring an additional 496,124 shares during the last quarter. BNP Paribas boosted its stake in shares of CVS Health by 105.2% in the 2nd quarter. BNP Paribas now owns 49,971 shares of the pharmacy operator's stock valued at $5,154,000 after purchasing an additional 25,617 shares during the last quarter. State Street Corp raised its position in shares of CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator's stock worth $4,776,182,000 after acquiring an additional 1,245,457 shares in the last quarter. Legal & General Group Plc increased its holdings in CVS Health by 0.3% in the fourth quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator's stock worth $738,777,000 after purchasing an additional 31,249 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in CVS Health by 28.4% in the fourth quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator's stock worth $370,333,000 after purchasing an additional 1,031,998 shares during the period. 80.66% of the stock is currently owned by institutional investors.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Updated 2026–2027 COVID-19 vaccines are now available at CVS Pharmacy and MinuteClinic locations nationwide. Most insured patients can receive them at no cost, with appointments available through CVS.com or the app and walk-ins accepted. The rollout could support pharmacy and clinic traffic, although its financial impact is likely modest. Updated COVID-19 Vaccines Available at CVS Pharmacy and MinuteClinic
• Positive Sentiment: Analysts and financial commentators point to CVS’s pharmacy growth, specialty-pharmacy expansion, AI investments, GLP-1 opportunities and potential Aetna margin recovery as drivers of a turnaround. Recent quarterly results showed revenue of $106.1 billion, up 7.3% year over year, while adjusted operating income reportedly rose 35%. CVS Health: Buy the Pullback Before Earnings Power Ramps Up
• Positive Sentiment: CVS is being viewed as attractively valued, with commentary citing roughly 12-times forward earnings versus healthcare peers. Its latest reported adjusted EPS of $2.58 exceeded the $1.87 consensus estimate, and full-year 2026 guidance remains $7.90–$8.10 per share. Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?
• Neutral Sentiment: CVS’s 20-year community health-screening program and new survey emphasize unmet demand for preventive care. The initiative may strengthen the company’s community-health brand, but the announcement is primarily reputational rather than a near-term earnings catalyst. CVS Health Marks 20 Years of Free Community Health Screening
• Negative Sentiment: CVS flagged elevated medical expenses, renewing concerns about managed-care profitability and Aetna margins. Investors also continue to monitor reimbursement pressure and regulatory scrutiny, which could offset gains from pharmacy growth and leave the stock under pressure despite its discounted valuation. CVS Health Flags Elevated Medical Expenses

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Truist Financial raised their price objective on CVS Health from $108.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Wells Fargo & Company raised their price objective on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. JPMorgan Chase & Co. upped their target price on shares of CVS Health from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Robert W. Baird set a $107.00 target price on shares of CVS Health in a report on Thursday, August 6th. Finally, Sanford C. Bernstein restated an "outperform" rating and set a $112.00 price target on shares of CVS Health in a report on Wednesday. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $107.24.

CVS Health Stock Performance

NYSE:CVS opened at $95.31 on Friday. The company has a market capitalization of $121.90 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 0.93 and a beta of 0.59. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68. The business has a 50 day moving average of $100.12 and a 200 day moving average of $90.74. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm's quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health's dividend payout ratio (DPR) is presently 70.37%.

About CVS Health

CVS Health Corporation is an American health care company headquartered in Woonsocket, Rhode Island. Founded in 1963 as Consumer Value Stores, the company has expanded from a chain of retail pharmacies into an integrated health care organization serving consumers, employers, health plans, government programs and health care providers.

CVS Health operates through several major businesses. Its Health Care Benefits segment, anchored by Aetna, provides health insurance products and related services for employers, individuals, Medicare and Medicaid members.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.